HC Wainwright Lowers ProPhase Labs (NASDAQ:PRPH) Price Target to $14.00

ProPhase Labs (NASDAQ:PRPHGet Rating) had its price objective decreased by investment analysts at HC Wainwright from $16.00 to $14.00 in a note issued to investors on Monday, The Fly reports. HC Wainwright’s price objective points to a potential upside of 89.45% from the stock’s current price.

A number of other research analysts have also recently commented on PRPH. Zacks Investment Research raised shares of ProPhase Labs from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a report on Tuesday, February 22nd. TheStreet raised shares of ProPhase Labs from a “d+” rating to a “c-” rating in a report on Monday, March 28th. Finally, StockNews.com assumed coverage on shares of ProPhase Labs in a report on Friday. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.88.

Shares of PRPH stock traded up $0.36 on Monday, reaching $7.39. The company had a trading volume of 3 shares, compared to its average volume of 24,939. The stock has a market capitalization of $114.44 million and a PE ratio of 7.32. The company has a quick ratio of 3.65, a current ratio of 3.95 and a debt-to-equity ratio of 0.17. ProPhase Labs has a one year low of $4.44 and a one year high of $8.58. The business’s 50-day moving average is $7.24 and its 200 day moving average is $6.92.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Morgan Stanley increased its position in ProPhase Labs by 354.6% during the 1st quarter. Morgan Stanley now owns 10,592 shares of the company’s stock valued at $78,000 after purchasing an additional 8,262 shares during the period. Bank of America Corp DE acquired a new stake in ProPhase Labs during the 2nd quarter valued at approximately $177,000. Millennium Management LLC increased its position in ProPhase Labs by 165.1% during the 2nd quarter. Millennium Management LLC now owns 46,575 shares of the company’s stock valued at $289,000 after purchasing an additional 29,008 shares during the period. BlackRock Inc. increased its position in ProPhase Labs by 14.5% during the 3rd quarter. BlackRock Inc. now owns 28,778 shares of the company’s stock valued at $150,000 after purchasing an additional 3,647 shares during the period. Finally, Perritt Capital Management Inc. increased its position in ProPhase Labs by 5.9% during the 3rd quarter. Perritt Capital Management Inc. now owns 188,400 shares of the company’s stock valued at $980,000 after purchasing an additional 10,500 shares during the period. Institutional investors and hedge funds own 9.75% of the company’s stock.

About ProPhase Labs (Get Rating)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Featured Stories

The Fly logo

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.